Early reperfusion with percutaneous transluminal coro nary intervention has been shown to be effective in reducing myocardial infarct size and improving car diac function, but data from clinical trials to evaluate the efficacy of adjunctive therapies in further redu cing myo cardial infarct size have been disappointing 1, 2 . Consequently, despite the improvements in timeto reperfusion for STsegment elevation myocardial infarc tion (STEMI) and the use of evidencebased therapies during hospitalization in the past decade, inhospital mortality for STEMI has not declined 3 . According to the AHA, 30day mortality in patients presenting with myocardial infarction (MI) is as high as 7. 8-11.4% 4 . Up to 18% of men and 23% of women aged ≥45 years will die within 1 year of their first MI event; these rates increase to 36% and 47%, respectively, up to 5 years after the initial event. In addition, among the survivors in this population, 16% of men and 22% of women will develop heart failure 4 . Several reasons have been proposed to explain why adjunctive therapies have not been effective in reducing infarct size and improving outcomes after MI in the clinical trial setting, includ ing the lack of reproducibility and rigour in preclinical studies; use of preclinical models that do not adequately reflect clinical comorbidities such as advanced age; and administration of pharmaco logical agents too late to have an effect on infarct size. Furthermore, antiplatelet agents such as P2Y 12 receptor blockers are commonly prescribed to these patients before primary angioplasty, and might mask the protective postconditioning effects of adjunctive therapies 5 . In the setting of acute MI, these antiplatelet agents help to maintain vessel patency after percutaneous coronary intervention (PCI). In addition to their effects on platelet aggregation, these drugs are power ful postconditioning mimetics, and act on the same protective signalling pathways that are activated during ischaemic preconditioning or post conditioning 6, 7 . As a consequence, therapeutic strategies that target ischae mic preconditioning 8 or postconditioning 6 as a means for cardio protection after MI did not reduce infarct size in animal hearts beyond the effects of the antiplatelet agents. The first clinical trial to evalu ate the efficacy of ischaemic postconditioning after acute MI reported promising findings, but subsequent trials that were con ducted after platelet inhibitors came into widespread use in patients undergoing PCI yielded either neutral results, or demonstrated only marginal benefit with post conditioning 5, 9, 10 . Although the use of platelet inhib itors might not be the only confounding factor in these studies, any intervention that cannot prov ide additional cardioprotective effects beyond that of an antiplatelet agent in the setting of MI (as seen in the animal stud ies) is unlikely to improve outcomes. Remote ischaemic condition ing -whereby short, serial episodes of ischae mia and reperfusion applied to a (limb) vascular bed confer global protection against subsequent ischaemiareperfusion injury -has been shown to reduce myo cardial infarct size in several contemporary clinical trials Abstract | Early coronary artery reperfusion improves outcomes for patients with ST-segment elevation myocardial infarction (STEMI), but morbidity and mortality after STEMI remain unacceptably high. The primary deficits seen in these patients include inadequate pump function, owing to rapid infarction of muscle in the first few hours of treatment, and adverse remodelling of the heart in the months that follow. Given that attempts to further reduce myocardial infarct size beyond early reperfusion in clinical trials have so far been disappointing, effective therapies are still needed to protect the reperfused myocardium. In this Review, we discuss several approaches to preserving the reperfused heart, such as therapies that target the mechanisms involved in mitochondrial bioenergetics, pyroptosis, and autophagy, as well as treatments that harness the cardioprotective properties of inhaled anaesthetic agents. We also discuss potential therapies focused on correcting the no-reflow phenomenon and its effect on healing and adverse left ventricular remodelling.
. Consequently, despite the improvements in timeto reperfusion for STsegment elevation myocardial infarc tion (STEMI) and the use of evidencebased therapies during hospitalization in the past decade, inhospital mortality for STEMI has not declined 3 . According to the AHA, 30day mortality in patients presenting with myocardial infarction (MI) is as high as 7.8-11.4% 4 . Up to 18% of men and 23% of women aged ≥45 years will die within 1 year of their first MI event; these rates increase to 36% and 47%, respectively, up to 5 years after the initial event. In addition, among the survivors in this population, 16% of men and 22% of women will develop heart failure 4 . Several reasons have been proposed to explain why adjunctive therapies have not been effective in reducing infarct size and improving outcomes after MI in the clinical trial setting, includ ing the lack of reproducibility and rigour in preclinical studies; use of preclinical models that do not adequately reflect clinical comorbidities such as advanced age; and administration of pharmaco logical agents too late to have an effect on infarct size. Furthermore, antiplatelet agents such as P2Y 12 receptor blockers are commonly prescribed to these patients before primary angioplasty, and might mask the protective postconditioning effects of adjunctive therapies 5 . In the setting of acute MI, these antiplatelet agents help to maintain vessel patency after percutaneous coronary intervention (PCI). In addition to their effects on platelet aggregation, these drugs are power ful postconditioning mimetics, and act on the same protective signalling pathways that are activated during ischaemic preconditioning or post conditioning 6, 7 . As a consequence, therapeutic strategies that target ischae mic preconditioning 8 or postconditioning 6 as a means for cardio protection after MI did not reduce infarct size in animal hearts beyond the effects of the antiplatelet agents. The first clinical trial to evalu ate the efficacy of ischaemic postconditioning after acute MI reported promising findings, but subsequent trials that were con ducted after platelet inhibitors came into widespread use in patients undergoing PCI yielded either neutral results, or demonstrated only marginal benefit with post conditioning 5, 9, 10 . Although the use of platelet inhib itors might not be the only confounding factor in these studies, any intervention that cannot prov ide additional cardioprotective effects beyond that of an antiplatelet agent in the setting of MI (as seen in the animal stud ies) is unlikely to improve outcomes. Remote ischaemic condition ing -whereby short, serial episodes of ischae mia and reperfusion applied to a (limb) vascular bed confer global protection against subsequent ischaemiareperfusion injury -has been shown to reduce myo cardial infarct size in several contemporary clinical trials and metaanalyses [11] [12] [13] [14] . The mechanisms involved in remote ischaemic conditioning are currently unknown and have not been tested against platelet inhibitors.
In light of these observations, an optimal strategy for preserving the myocardium after MI will be one that miti gates a factor contributing to cell death in the reper fused heart, but is not targeted by platelet inhibitors. For exam ple, mild hypothermia and sodium-hydrogen exchange blockers offer additive protection against infarction when combined with the P2Y 12 inhibitor cangrelor in rats; the use of all three strategies in combination is three times as protective against infarction compared with the use of the platelet inhibitor alone 8 . Unfortunately, mild hypothermia and sodium-hydrogen exchange blockers seem to target ischaemic tissue rather reperfused tissue, and thus these strategies must be applied during ischaemia for optimal efficacy 15 . Although investigations exploring the effects of rapid cooling (either soon after admission or even in the ambulance to shorten the normothermic ischaemic time) are ongoing 16 , a better solution would be to develop an intervention that is effective when administered around the time of reperfusion. Future investigations of cardio protective agents should include experiments in animal models with common clinical comorbidities and in com bination with platelet inhib itors to identify therapies most likely to translate to the clinical situation.
Infarct size reduction is not the only therapeutic goal after MI. Longterm therapy with angiotensin convertingenzyme inhibitors, angiotensin receptor blockers, and/or βblockers reduces adverse left ventricu lar (LV) remodelling, but has only modest effects on mortal ity 17 . Whereas stem cell therapy has shown prom ise in some studies, most of the larger clinical trials yielded either neutral findings or demonstrated very limited improvements in LV ejection fraction after MI 18 . The promising preclinical results in periprocedural MI stem cell therapy have not yet translated into clin ical bene fit for patients 18 . However, cell mimetic thera pies such as nanoparticles 19 and synthetic stem cells 20 engin eered to mimic stem cell trophic effects are in preclinical stages of develop ment. This field of research highlights the major unmet need for noncellular thera pies that can improve cardiac structure and function after MI, perhaps in associ ation with cell therapy. In this Review, we consider several promising approaches for the preservation of cardiac structure and function after MI that are not currently part of the clinical armamen tarium (FIG. 1) . This Review takes a broader approach than previously published Reviews on cardioprotection focused on preconditioning, postconditioning, and remote ischaemic conditioning, plus their pharmaco logical mimetics 1, 2, 21, 22 . We discuss cardio protective mechanisms that target mitochondrial bioenergetics, anaesthetic preconditioning, pyroptosis, autophagy, and the noreflow phenomenon. All these therapies involve mitochondrial function to some extent, such that pro gress in each of the approaches should inform the others. Indeed, a newly listed clinical trial involving the trans plantation of auto logous skeletal muscle mitochondria epicardially in children undergoing extracorporeal membrane oxygenation after ischaemic injury points to the emerging importance of bioenergetic approaches for heart disease 23 .
Targeting the mitochondria Bioenergetics and ROS generation
The pathophysiology of cardiac reperfusion injury is complex, and varies over time after injury. Altered ion homeostasis, inflammation, activation of adaptive sig nalling pathways, metabolic substrate utilization shifts, and mitochondrial dysfunction are among the many factors that contribute to electromechanical dysfunc tion and tissue injury. The mitochondria are complex structures that undergo biogenesis, fission, and fusion independent of cell cycling. As central hubs of cellu lar energetics and redox signalling, the mitochondria influence virtually all cellular functions, particularly cell survival. They have been identified as a drug target in ischaemic heart disease, given the negative effects of increased gener ation of reactive oxygen species (ROS), abnormal cellular energetics, and impaired mito chondrial ion homeo stasis on cardiac structure and function (FIG. 2 
24-27 . Mitochondrial functional
Key points
• Mortality after acute ST-segment elevation myocardial infarction (STEMI) has plateaued in the past decade, after a period of continual decline • Beyond early reperfusion, a variety of adjunctive agents to reduce myocardial infarction after reperfusion have been tested in clinical settings, and have yielded largely disappointing results • Before clinical testing, candidate cardioprotective agents should be tested in animal models with comorbidities similar to that in patients, and in combination with P2Y 12 inhibitors • Approaches for improving cardiac function following STEMI that have been promising in preclinical studies include those that target mitochondrial bioenergetics, pyroptosis, autophagy, and no-reflow and anaesthetic preconditioning aberrations are often inter related, such as imbalances in calcium and sodium ion levels, opening of energy dissipating channels or pores, and increased production of ROS [27] [28] [29] [30] . Formation of excess reactive oxygen intermediates, many of which originate from within the electron trans port system and the mitochondrial matrix 31, 32 , NADPH oxidase 33 , and catecholamine catabolism via mono amine oxidases 34, 35 , cause cellular pathology in many acute and chronic diseases. A small amount of ROS prod uction is essential for normal physiological signalling, but at higher levels, ROS are toxic [36] [37] [38] [39] [40] [41] . During acute reper fusion injury, the rate of ROS production substantially outpaces the capacity of endogenous scaven gers to reduce them. A number of strategies to eliminate ROSmediated damage in the early reper fusion window have been clin ically tested, but with limited success [42] [43] [44] [45] [46] . A major source of mitochondrial ROS in early reper fusion seems to be from increased succinate levels during the ischaemic period 47 , which is postulated to produce ROS by 'reverse electron transfer' . ROS are released from mitochondria into respiratory complexes called supercomplexes, func tional aggregates of the electron transport system that are essential for normal electron flux [48] [49] [50] [51] . Fewer respir atory supercomplexes are formed in the setting of acute 52 and chronic 53,54 cardiac pathologies. Since ROS produc tion seems to be inversely related to supercomplex for mation 55 , the loss of supercomplexes might be directly linked to augmented ROS production in a 'vicious cycle' . Interventions that promote sustained generation of super complexes might have the potential to reduce myocardial injury during ischaemia and reperfusion 25 .
Direct scavengers of ROS. Direct scavenging of radicals has long been proposed as a potential treatment for reper fusion injury 25, 27 . Direct scavengers that lessen mito chondrial radical accumulation, such as the scavenger 2,2,6,6tetramethylpiperidine1oxyl (TEMPO; targeted to mitochondria via gramicidin XJB5131 (REFS 52,56)) or triphenylphosphonium (MitoTEMPO) 57 65, 66 . Coenzyme Q 10 (also known as ubiqui none) is an endogenous, freeradicalscavenging anti oxidant reported to be beneficial in preclinical models of ischaemia-reperfusion 67, 68 . Coenzyme Q 10 administra tion in patients with heart failure significantly reduced cardiac mortality 69 . Quinones that target mitochon dria, such as mitoQ 70 and SkQ 71 , are showing promise in preclinical studies. However, at higher doses, cation conjugates can inhibit mitochondrial function 72 . Ideally, future exogenous scavengers should be engineered for improved tissue permeability and more specific intracellular or mitochondrial targets.
Interventions that inhibit mitochondrial respir ation.
Transient, partial inhibition of mitochondrial respir ation during the vulnerable earlyreperfusion phase might also be cardioprotective by limiting mito chondrial ROS production. Rotenone 73 and several different biguanides (such as metformin) 74 inhibit complex I of the mito chondrial respiratory chain, and have been shown to be cardioprotective when administered after ischaemia 75, 76 . Notably, however, rotenone is a wellknown neurotoxin, and its systemic effects are likely to limit its use in this setting. Likewise, inhib ition of complex II (succinate dehydrogenase) with malonate (or the cell permeable precursor dimethyl malonate) has been shown to reduce ROS and decrease ischaemia-reperfusion injury 47, 77, 78 . Furthermore, post translational modification of elec tron transport complexes by Snitrosothiols (mitoSNO) that are engin eered to selectively block ROS protects mitochondrial function and lessens reper fusion injury in rodents [79] [80] [81] [82] [83] . The safety of salvaging tissue by tran siently blunting mitochondrial bio energetics must be determined before these approaches can be advanced to clinical trials. Furthermore, methods to target these strategies specifi cally to the heart (to avoid inhib iting respiration in other organ systems) must also be identified.
Interventions targeting post-translational modifications. Posttranslational modifications of electron trans port complexes and endogenous ROSscavengers via sirtuins 84 and OGlcNAc modifications 85 , or succinyl ation 86 might help in the search for novel pharmaco logical interventions to treat postischaemic injury. Given that the adaptor protein p66
Shc catalyses ROS formation via cytochrome c, several studies have investi gated the potential role of p66
Shc as a regulator of myocardial injury in murine models of cardiac ischaemia and reperfusion. Genetic lossoffunction studies have Nature Reviews | Cardiology Some of these strategies involve mitochondrial structure and function, whereas others involve anaesthetic preconditioning and reducing the no-reflow phenomenon, which might also involve the mitochondria.
yielded opposing findings regarding cardiac injury 87, 88 . Isolated hearts from p66
Shc knockout mice were pro tected against acute reperfusion injury
88
. However, a sub sequent investigation assessing ischaemia-reperfusion in vivo found that neither knockout mice nor transient transfection with p66
Shc small interfering RNA imparted cardioprotection 87 , and was actually deleterious. These differences might be related to inherent discrepancies between in vivo versus in vitro studies, as well as differ ing durations of ischaemic insult across studies. Further research is warranted to fully understand the role of p66
Shc signalling and posttranslational modifications in reperfusion injury 89 .
Interventions targeting mitochondrial membrane potential. Interventions to improve mitochondrial function often focus on mitochondrial membrane potential (Δψ m ). The transmembrane potential of mito chondria is established by electrondependent proton pumping, and serves as the major energetic driver for the replenishment of ATP, cellular redox buffering, and ion/metabolite transport. Loss of Δψ m during cardiac ischaemia-reperfusion is thought to be directly related to cellular injury and electromechanical dysfunction, as seen in in vitro models and intact hearts subjected to ischaemia-reperfusion injury 28, 43, [90] [91] [92] [93] . Aon and col leagues hypothesized that pathophysiological ROS over flow occurs at both minimal and maximal Δψ m
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. Highly polarized Δψ m is observed in mitochondria that are 'idling' (that is, mitochondrial respiration with little to no ATP turnover), suggesting that slight uncoupl ing might protect mitochondria by reducing ROS formation 95 .
Although this strategy has been used to treat other diseases influenced by mitochondrial dysfunction 96 , mild uncoupling in the heart did not markedly reduce mitochondrial ROS production 97 , and actually led to increased ROS prod uction in isolated myocytes 98 . Numerous studies have shown that cardioprotection is associated with sustained, polarized Δψ m ; this energized Δψ m is essential during metabolic insult to replenish endogenous antioxidants via NADPHlinked reactions, which allows for the downstream detoxification of free radicals 99, 100 . Cardioprotection inferred by sustained Δψ m has been observed after exercise pre conditioning 91 , after administering serofendic acid (a cardioprotective substance found in fetal calf serum which inhibits the oxidant induced mitochondrial death pathway 101 ), or by blocking energydissipating ion channels within the mitochondrial inner membrane 102, 103 . A reduction in Δψ m is an early step in programmed cell death 104 , a process considered irreversible after the apoptotic cascade is initiated. However, even after activ ation of caspase 3 and DNA nicking, some cells (including primary cardiomyocytes) can recover through a process known as anastasis 105 . Caspase 3 is used extensively in normal development and in adult organ remodel ling, so strategies that can activate the non apoptotic proper ties of caspase 3 after cellular injury might prov ide a potential intervention for cardioprotection after ischaemia-reperfusion 106 .
The mitochondrial PTP Potential strategies to preserve mitochondrial bio energetics by targeting the permeability transition pore (PTP) have received considerable interest, and have been the subject of numerous reviews [107] [108] [109] [110] . Inhibition of PTP at reperfusion is thought to be a primary mechanism by which ischaemic preconditioning and postconditioning protect the heart 108, 111 . As calcium and ROS are postu lated to increase the probability of the opening of the PTP, strategies that reduce ROS and lower mitochon drial calcium overload have been extensively explored as cardioprotective interventions 25, 27 . Paradoxically, transient PTP opening seems to reduce mitochondrial calcium overload, analogous to a ' pressure release valve' , whereby mitochondrial calcium decreases upon tran sient PTP opening 112 . This mech anism works to reset mitochondrial calcium concentration, and is postu lated to prevent the sustained, large conductance, open conformation of PTP that is associ ated with patho logical injury and cell death. Studies published in the past 6 years suggest that the PTP is also comprised of ATPsynthase (complex V) dimers and associated regulatory proteins 113, 114 . Use of the PTP blocker cyclosporine A for the treat ment of acute coronary syndromes initially showed promise in small trials 115, 116 , but a larger multicentre trial yielded neutral findings 117 . TRO40303, a ligand of the putative PTP component translocator protein (also called the peripheral benzodiazepine receptor), did not impart any cardioprotective benefits in patients with MI 118 . The underlying factors involved in these neutral findings are clearly multifaceted; of note, however, Nature Reviews | Cardiology most patients involved in PCI trials since 2005 have received platelet inhibitors as a standard ofcare ther apy. As platelet inhibitors can independently protect the heart by inhibiting the PTP 6, 7, 119 , patients enrolled in trials that assessed the efficacy of PTP blockers might already be 'conditioned' against injury. Importantly, cyclosporine and this 'conditioning' effect do not prevent PTP opening, but instead simply raise the threshold for opening. The development of strat egies targeting hexokinase (a regulator of PTP opening) to mitochondria [120] [121] [122] , as well as more specific PTP block ers that target mitochondria 123 might lead to new thera pies for the treatment of ischaemia-reperfusion injury. Several other mitochondrial approaches to protect the heart in this setting are also under develop ment, including methods to deliver autologously derived mitochondria [124] [125] [126] , new mitochondriatargeting pep tides 43, [127] [128] [129] [130] , strategies that target calciumactivated mitochondrial potassium channels 131 or block ATP sensitive potassium channels [132] [133] [134] , and approaches that block the inflammation caused by mitochondrial DNA after MI 135, 136 .
Challenges and opportunities
Given the role of the mitochondria in reperfusion injury, novel compounds targeted towards altering mito chondrial bioenergetics might reduce myocardial injury. However, delivery of these compounds to mitochondria poses as a daunting problem. Timing is a major con cern, because the compound must reach therapeutic lev els during the appropriate window, which is often early in reperfusion. Given the importance of minimizing 'doortoballoon' times, achieving therapeutic levels in time with systemic delivery is challenging; direct coro nary catheter administration might be more feasible for reducing acute injury. Bioavailability of the compound poses a further challenge, because the compound must resist degradation (or sequestration) in the circulation, traverse the capillary network and cross cell membranes, and then localize to mitochondria. Medicinal chem istry considerations for mitochondriatargeted thera pies include whether the targeting moiety is cleaved inside cells, as well as appropriate chemical linkers and positions to which the cargo should be attached on the parent mitochondriatargeting molecule. Despite these obstacles, a number of putative mitochondriatargeting strategies are emerging.
The highly negative Δψ m of healthy mitochondria is frequently utilized as an attractant to deliver mito chondrial cargo via positively charged carriers. The most wellcharacterized conjugate family to date uses triphenylphosphonium, a cationic lipophile, to deliver therapies to mitochondria 30, [137] [138] [139] . A similar approach is being developed using plantderived cellpermeable cations such as berberine or palmatine 140, 141 , although some of these compounds can inhibit respiration at low micromolar concentrations 72 . Peptide conjugates are another emerging therapy targeted to mitochondria. Multiple peptide sequences containing alternating cationic and hydrophobic amino acids show cell permeability and mitochondrial localiza tion, and are being developed as delivery vectors 142 . Examples of these peptides include mitochondria penetrating peptides 143, 144 and several of the SzetoSchiller peptides 145 . The ROS scavenger XJB5131 conjugates the scavenging TEMPO moiety to mito chondria via a gramici din peptide sequence 56 ; this sequence might be useful to deliver other cargo to mitochondria. Nano particles have also been developed to reduce cardiac mitochondrial injury 146, 147 , although the nano particle vector might be more important for enhancing cellular uptake in damaged cells than for mitochondrial localiza tion per se. However, cardiac toxicity has been observed with several types of nanoparticles 148, 149 , indicating that more research is needed to develop these agents. Continued investigation into the safety and efficacy of vectors that deliver cargo to mitochondria is an exciting area for cardioprotective therapies.
Anaesthetic preconditioning
Clinical studies of anaesthetic conditioning of the heart have focused almost entirely on preconditioning and on patients undergoing cardiac surgery, for practical reasons -anaesthesiologists are present at the critical time before the coronaries are reperfused. Substantially less work on anaesthetic preconditioning has been conducted in MI models, and on anaesthetic post conditioning after cardiac surgery, despite the technique having therapeutic potential in these settings as well. Similar to ischaemic preconditioning, short exposure of the heart to halogen ated volatile anaesthetics offers cardioprotection against subsequent ischaemic or ischaemia-reperfusion injury 150 . Pharmacological studies suggest that the mechanisms of anaesthetic and ischaemic preconditioning are similar. Volatile anaesthetic preconditioning is complex, and involves agents that increase mitochondrial ROS prod uction; activate protein kinase C (PKC), extracellular signalrelated kinase (ERK1/2, also known as mitogen activated protein kinase 3 and 1), and Akt (also known as Racα serine/threonineprotein kinase); open K ATP channels acutely; and reduce myocardial oxygen con sumption [151] [152] [153] . Given these signalling pathways are the same as those targeted by P2Y 12 platelet inhibitors, anaes thetic preconditioning is not likely to provide additional protection in patients undergoing PCI who are treated with platelet inhibitors. Patients who are naive to these drugs, such as those undergoing cardiac surgery, are more likely to respond to anaesthetic preconditioning. Data from preclinical studies suggest that activ ation of aldehyde dehydrogenase 2 by mitochondrial protein kinase Cε (PKCε) is necessary for effective anaesthetic preconditioning 154 , as well as inactivation of cardiac Ltype calcium channels 155 and increased production of heat shock protein 90 (and its induction of endothelial nitric oxide synthase) 156 . Longerterm cardiac protec tion by anaesthetic preconditioning might be mediated through downstream effectors of hypoxia inducible factor 1 (REF. 157 ), but its mechanism of action in this set ting is unclear. The first doubleblind, placebo controlled trial of anaesthetic precondition ing in patients under going cardiac surgery used sevoflurane (5 min inhal ation before cardioplegia) on a background of opioid mainten ance anaesthesia 158 . Standard clin ical lab oratory evidence of MI (cardiac enzymes) were unaffected by this preconditioning regimen, but preconditioning reduced Btype natriuretic peptide levels. Atrial biop sies showed translocation of PKCε to the sarco lemma, mitochondria, and inter calated disks of cardio myocytes after precondition ing 158 . Unsurprisingly to anaesthesio logists, treated patients required substantially more pressor support during preconditioning, but still had better glomerular filtration rates after CABG surgery than untreated patients, suggesting a pre conditioning effect on the kidneys. Subsequent studies also reported cardioprotection with use of various inhaled anaes thetics after CABG surgery, but these effects were not potent enough to change major outcome variables 159, 160 . In theory, an increase in dosage should lead to an increase in potency, but acute increases in the concen tration of inhaled anaesthetics can lead to hypotension and cardiac depression. Similarly, intraoperative remote ischaemic preconditioning (via cuff inflation-deflation on the leg) added to isoflurane preconditioning did not increase the potency of anaesthetic preconditioning, and might even blunt the anaesthetic effect 159 .
Challenges and potential confounders
With a gradual increase in experience with applica tion of anaesthetic preconditioning during CABG surgery, researchers found that the benefits of anaes thetic preconditioning for cardiac ischaemic events in animal models were not readily translated to humans. The heterogeneity of patients is often unmasked when translating studies from inbred rodent models to the clinic. Furthermore, most animal studies are performed in young animals, whereas most patients undergoing CABG surgery are not young, and senescent hearts are difficult to precondition, even in animal models 161 . Variables that can affect outcomes after cardiac sur gery, such as other drugs, fluids, electrolytes, trans fusions, and physiological gases administered, can be very difficult to control for in clinical studies. Further more, the inflammatory and oxidative stressinduced damage caused by ischaemia-reperfusion injuries are difficult to avoid in the operating room, as are presurgical comorbidities.
Hyperglycaemia, in particular, blunts anaesthetic preconditioning, in part by disruption of mitochon drial bioenergetics 162 . A study using human induced pluripotent stem cell (iPSC)derived cardiomyocytes showed that opening of mitochondrial potassium channels was disrupted in the presence of high glucose levels 163 . Given the difficulty in designing clinical trials to assess the efficacy of anaesthetic preconditioning, and the slow progress in optimizing this technique owing to the complexity of cardiac surgery, human iPSC derived cardiomyocytes are an important platform for probing anaesthetic preconditioning. These cells provide an opportunity for rigor ous assessment of issues such as timing and amount of preconditioning, changes in molecular mediators of preconditioning as a function of genetic background and the cellular microenvironment, and potential synergistic combinations of anaesthetics and other drugs, all of which are nearly impossible to measure in the clinical setting. Combined with stand ard preclinical models, human iPSC technology should provide a platform for revisiting clinical anaesthetic pre conditioning that allows assessment of the mechanisms underlying the anaesthetic effects.
Pyroptosis and the innate immune system A study published in 2015 reported that strategies to pre vent the escape of mitochondrial DNA (mtDNA) from ruptured mitochondria can be cardioprotective in the setting of infarction when applied just before reperfu sion 136 . Two approaches were tested: the first involved mitochondrialdirected glycosylase, which removes oxid ized bases from mtDNA created during reperfu sion, thus favouring mtDNA repair over its release; and the second strategy involved use of intravenous DNase I, which degrades any extracellular DNA. The effect of both of these interventions on infarctrelated injury were similar to that of conditioning, and most importantly, offers additive protection when combined with a P2Y 12 inhibitor in animal models, suggesting that mechanism of mtDNA toxicity cannot be addressed by P2Y 12 inhib itor administration alone. Therefore, strategies target ing released mtDNA are likely to be cardioprotective in patients who are already undergoing P2Y 12 inhibitor treatment, and warrant further investigation.
The most likely explanation for the toxicity of mtDNA is inflammation, one of the earliest proposed mechanisms of cell death from ischaemia-reperfusion injury. In the 1980s, studies of inflammatory responses concentrated on leukocytes, because they quickly accumu late in large numbers in ischaemic tissue 164 . Although leukocytes are involved in cell death after MI, most approaches to prevent their accumulation did not limit infarction, and interest in this strategy subsequently waned 164 . In 2014, a reassessment of inflammation in ischaemia focused specifically on the innate immune system 165 . FIGURE 3 shows a diagram of the NLRP3 (also known as NACHT, LRR, and PYD domainscontaining protein 3) inflammasome, an important component of the innate immune system. Invading pathogens release pathogenassociated molecular patterns (PAMPs) that signal the presence of sepsis. These PAMPs initiate interleukin and interferon production through the Tolllike receptor (TLR) system, whereby TLR4 recog nizes lipopolysaccharide and TLR9 recognizes bacterial DNA. This sequence of events is often referred to as signal 1. PAMPs also trigger the assembly of the inflamma some, in a process known as signal 2. NLRP3 combines with the adaptor protein apoptosisassociated specklike protein containing a CARD (ASC) and pro caspase 1 to form active caspase 1. Caspase 1, in turn, cleaves pro interleukins to form active IL1β and IL18 (REF. 166 ). Caspase 1 can also liberate the Nterminal segment of gasdermin D, which creates pores in the cell mem brane, in a process known as pyroptosis. These membrane pores allow cytokines to exit the cell and call inflammatory cells to attack the invader, but they also inevitably kill the cell 167, 168 . Sepsis is not the only trigger for inflammasome formation. Damageassociated molecular patterns (DAMPs) from injured tissue, such as mtDNA, can also trigger the formation of inflammasomes 169 . Reperfusion causes a burst of oxygen radicals in the mitochondria, which oxidizes bases in the mtDNA and promotes the opening of the PTP through which oxidized mtDNA fragments flow into the cytosol 170 . With its many unmethylated stretches of DNA in which the frequency of a cytosine immediately followed by a guanine is high, these mtDNA fragments resemble bacterial DNA, are TLR9 ligands, and are potent inducers of the NLRP3 inflammasome 171 . Extracellular mtDNA is a potent proinflammatory DAMP in traumatic shock 172 and in ventilatorinduced lung injury 173 . Infusing mtDNA into the coronary artery increases infarct size in Krebs bufferperfused rat hearts 136 ; similarly, mtDNA added to culture medium induces cell death in cultured cardiomyocytes 174 , indicating that mtDNA triggers cytotoxic pathways in the heart's paren chymal cells rather than just in the circulating white cells. Investigations into the role of the NLRP3 inflamma some in ischaemic injury have yielded mixed findings, with some studies reporting increased resistance to infarc tion in hearts in which NLRP3 inflamma some has been genetically deleted 175, 176 , and others reporting neutral findings 177, 178 . Importantly, the NLRP3 inflammasome is not the only activator of caspase 1; at least three other similar inflammasome systems that activate caspase 1 have been described 179 , which might explain why chronic deletion of the NLRP3 inflamma some might be com pensated for by activation of another inflammasome. Several pharmacological NLRP3 inhibitors have been developed, which have all been effective in limiting infarct size in animal models [180] [181] [182] . Attempts to mitigate caspase 1mediated damage have yielded more consistently positive findings. In 2001, a study involving human atrial trabeculae subjected to simulated ischaemia-reperfusion showed that inhibition of caspase 1 with a highly selective inhibitor (AcYVAD cmk) preserved contractile function 176 . IL18 binding protein and an IL1 receptor blocker were similarly protective, suggesting that interleukins were involved in mediating the injury. AcYVADcmk was also found to reduce infarct size in an openchest rabbit model of surgically induced MI 183 . Furthermore, caspase 1 over expression in mice increased infarct size after ischaemiareperfusion by 50%, whereas complete knockout of caspase 1 reduced infarct size 175, 184 .The pancaspase inhibitor zVAD has also been reported to reduce infarct size 185, 186 ; caspase inhibition using zVAD was assumed to target apoptosis, a process which involves caspase 3 and caspase 9, but the action of caspase 1 would have also been inhibited. Unlike necrosis and pyroptosis, apoptosis does not result in rapid membrane failure and could not have accounted for the washout of dehydro genase enzymes in the studies of myocardial ischaemiareperfusion 187 . However, the apoptotic process seems to be involved in the release of the mtDNA that triggers inflammasome activation 188 . Caspase 1 not only prod uces cytotoxic cytokines, but also proteolytically cleaves several important glycolytic enzymes, including glycer aldehyde phosphate dehydrogen ase 189 . Loss of these glycolytic enzymes could contribute to infarction by impairing metabolic recovery during reperfusion. None of the aforementioned caspase 1 studies addressed the problem of possible redundancy with platelet inhibitors, but a study published in 2017 revealed that protection conferred by the highly selective caspase 1 inhibitor VX765 is additive to the protective effects of the P2Y 12 blocker cangrelor 190 . Nature Reviews | Cardiology and IL-18 by activating MyD88 (myeloid differentiation primary response protein 88), which activates the transcription factor nuclear factor-κB (NF-κB) through phosphorylation of the NF-κB inhibitor IκB. This phosphorylation in turn allows p50 (also known as NF-κB1) and p65 (also known as NF-κB p65 subunit) to dimerize, forming active NF-κB. When triggered by oxidized mitochondrial DNA in the cytosol, NLRP3 (NACHT, LRR, and PYD domains-containing protein 3), the adaptor protein ASC (also known as apoptosis-associated speck-like protein containing a CARD), and pro-caspase 1 form an inflammasome complex that results in the release of active caspase 1. The pro-interleukins are cleaved by caspase 1 into their active form. Caspase 1 also cleaves gasdermin D (GSDMD) to form its N-terminal fragment (GSDMD-nt) that creates holes in the membrane allowing the proinflammatory interleukins and caspase 1 to flow into the interstitial space. Membrane failure caused by those holes also kills the cell, a process termed pyroptosis. Finally, caspase 1 can proteolytically degrade many cytosolic enzymes that can cause further injury. Cyto c, cytochrome c; DeUBase, deubiquitinase; PAMPs, pathogen-associated molecular patterns.
Caspase 1 also inhibits autophagy (lysosomal mediated degradation) of mitochondria (also known as mitophagy) 191 . Given that mtDNA can promote inflammation in response to ischaemia-reperfusion, mitophagy might be cardioprotective in this setting. Under normal conditions, the body is careful not to release free mtDNA into the cytosol. When senescent mitochondria are eliminated by autophagy, they are enveloped in a vacuole and digested by enzymes such as DNase II. Complete knockout of DNase II produces a heart failure phenotype, which could be rescued using a TLR9 blocker, indicating that mtDNA that escaped from the vacuole was responsible for the phenotype 192 . Stimulating mitophagy at a time when mitochondria will be injured by ischaemia-reperfusion might attenuate mtDNA release, and could be yet another explanation as to why autophagy can reduce ischaemic injury.
Autophagy as a new therapeutic target Role in ischaemic preconditioning
Since the discovery of preconditioning in 1986, investi gators have sought to identify pharmacological triggers, elucidate the contributing signal transduction pathways, and define the mechanisms involved 193 . Autophagy is induced by many of the classic cardioprotective agents, including ischaemic preconditioning itself 194 , as well as diazoxide 194 , the adenosine A 1 receptor agon ist 2chloroN(6)cyclopentyladenosine 195 , sulfa phenazole 194 , rapamycin 196 , valsartan 197 , resveratrol 198 , nonsirtuin histone deactylase inhibitors 199 , and remote ischaemic conditioning 200 . Many investigators have demonstrated that autophagy is cardioprotective [201] [202] [203] , and several studies have demonstrated an absolute requirement for functional autophagy in cardio protection [194] [195] [196] [197] 204 . Furthermore, selective mitophagy has been shown to be essential for cardioprotection by ischaemic preconditioning 205 and statins 206 . Despite some early contradictory studies 207, 208 , autophagy is now generally regarded as cardioprotective when initiated before ischaemic stress. Although clearance of damaged mitochondria is undoubtedly an important protective consequence of autophagy, autophagy is likely to be cardioprotective through other mechanisms as well, including sequestration and degradation of glycogen, and removal of protein aggregates 209, 210 .
Role in postconditioning
The role of autophagy in postischaemic conditioning is more controversial, in part because of the complex roles and interpretation of autophagy markers. Detection of an increase in autophagosomes by immunostaining or the widely used autophagosome marker LC3II might indicate upregulation of autophagy, but could also mean impaired autophagosome clearance by lysosomes (impaired flux). Moreover, interventions that restore flux could be misinterpreted as downregulation of auto phagy 211 . Therefore, interpretation of autophagy stud ies must take into account whether flux was assessed. Most, but not all, reports support a beneficial role for autophagy in postconditioning [212] [213] [214] [215] .
Harmful effects
Autophagy often has a protective role in the heart, but in some settings might also be detrimental. For instance, autophagic cell death, or autosis, has been reported in the setting of cerebral ischaemia, and abrogation of auto phagy through gene silencing or chemical inhibitors can reduce cell death 216, 217 . Interestingly, a chemical screen identified cardiac glycosides (digoxin, digitoxigenin, and strophanthidin) as antagonists of autosis 218 . In the heart, less is known about the settings in which autosis might occur. Beclin 1 has been shown to be important in mediating autosis in the heart 219 , and haploinsufficiency of Beclin 1 might be cardioprotective 220 .
Regulatory pathways
Autophagy is primarily regulated by the nutrient sensing and energysensing pathways, namely mech anistic target of rapamycin (mTOR) and AMPdependent protein kinase (AMPK), respectively. However, multiple other signal transduction pathways are also involved in auto phagy, including forkhead box protein O1, p38 mitogen activated protein kinase, and Akt 2 (also known as RACβ serine/threonine protein kinase) 221 . Importantly, autophagy and mitophagy are regulated by sirtuins, a family of NADdependent protein deacetylases [222] [223] [224] . Numerous studies have revealed a role for microRNAs (miRNAs) in the regulation of cardiac autophagy; some of these miRNAs are in the circulation or are delivered via exosomes [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] . The term 'autophagoMIR' has been used to designate miRNAs that regulate autophagy, and includes both suppressors and activators of auto phagy (TABLE 1) . Importantly, miR144 delivered via exosomes has been implicated as a circulating effector of remote preconditioning 241 . miR30 targets Beclin 1, which has a dual role in initi ation of autophagy, but also can interfere with autophagic flux 242 . Therefore, down regulation of Beclin 1 can have unpredictable effects on autophagy, and autophagic flux should always be measured to allow for meaningful interpretation of autophagy studies. ATG, autophagy-related protein; BCL2, apoptosis regulator Bcl-2; FOXO3a, forkhead box protein O3a; GSK3β, glycogen synthase kinase-3β; LC3, microtubule-associated proteins 1A/1B light chain 3B; mTOR, serine/threonine-protein kinase mTOR; TSC1, hamartin.
Cardiac remodelling
The role of autophagy in cardiac remodelling is contro versial, with numerous studies reporting evidence for a protective role 209, 243, 244 , an adverse role 220 , or both 199, 245 . Autophagy has also been implicated in the pathologi cal role of angiotensin II on hypertrophy 246 , but its role in this setting is somewhat controversial 247 , and might be related to a functional dichotomy of autophagy or the nonspecific criteria for defining upregulated auto phagy. In the absence of measures of autophagic flux, misinterpretation of LC3 levels or autophagosome abundance is likely 211 . However, the roles for mitochon drial autophagy in cardiac homeostasis 248 , adaptation to stress 204, 249 , and handling of misfolded proteins 209 are well established.
Lifestyle factors
Autophagy is a homeostatic process that evolved from the need to survive episodes of nutritional depriv ation, and is invoked during sleep, when caloric intake is absent; chronic nutritional excess, however, eventu ally suppresses autophagy. Caloric restriction potently upregulates autophagy, and intermittent fasting -even in the absence of reduced caloric intake -can upregu late autophagy and benefit the heart 250, 251 . Similarly, timerestricted feeding (8 h per day) results in a period of fasting and can protect mice against the ill effects of a highfat diet 252 . A highfat diet has been shown to impair autophagy 253, 254 and reduce ischaemic toler ance 255 , underscoring the importance of intact auto phagic flux in cardioprotection. Like caloric restriction and intermittent fasting, exercise upregulates auto phagy and is associated with cardioprotection 256, 257 . Exerciseinduced autophagy is important for clearing protein aggregates and ameliorates cardiac proteino pathy; the beneficial effects of exercise were enhanced in mice with an overexpression of autophagyrelated protein 7 (REF. 209 ).
Cardioprotective effects of autophagy
Autophagy fulfils many roles in the heart. During ischaemia, autophagy provides amino acids and mono saccharides (from glycogenolysis) for ATP production, and is also essential for clearance of protein aggregates that accumulate in both heritable proteinopathies and in acquired heart failure 209 . During both ischaemiareperfusion and pressure overload, autophagy serves to sequester and degrade damaged mitochondria that might otherwise trigger apoptosis or necroptosis. Moreover, autophagy is important in preventing the activation of the innate immune system (TLR9 and NLRP3), which can be triggered by mitochondrial cardio lipin, mtDNA, and oxidized mtDNA 188, 192, 258 . Finally, mitophagy is important for mitochondrial qual ity control. Loss of oxidative phosphorylation capacity, whether through protein damage or mtDNA mutations, results in lower membrane potential, and mitophagy selectively eliminates the least functional organelles. Emerging evidence reveals a link between mitophagy and mitochondrial biogenesis 259, 260 , so that after elimin ating damaged organelles, a stimulus expands the mitochondrial pool to restore ATP production capacity. One important benefit of mitophagy might be the activ ation of mitochondrial biogenesis, which would facili tate mitochondrial quality control. Indeed, exercise training, known to upregulate autophagy and protect against MI, has also been shown to improve myocardial energy metabolism and enhance mitochondrial bio genesis 260 . In addition to intermittent fasting and exer cise, drugs that enhance mitophagy and biogenesis are also cardioprotective, and include statins 261 and NAD, which activates sirtuins 262 ; this list is likely to expand to include preconditioning and postconditioning agents.
Fragmented mitochondria have been observed in numerous disease states in the heart, and targeting mito chondrial dynamics might be another area for therapeu tic development 263 . Inhibition of mitochondrial fission has been shown to protect cardiac cells from reper fusion injury 264 . Treatment with a pharmacological inhibitor of Drp1dependent fission, mitochondrial division inhib itor 1 (Mdivi1), protects the heart when administered either directly 264 or as a nanoparticle conjugate 146 . These strategies are postulated to prevent mitochondrial outer membrane permeabilization, which is triggered by Bax translocation during ischaemia-reperfusion, resulting in cytochrome c release and the onset of cell death cas cades 265 . However, Drp1 (the target of Mdivi1), has been shown to mitigate mitochondrial dysfunction and heart failure in a pressureoverload model 243 .
No-reflow as a therapeutic target
In the setting of acute MI, noreflow is defined as a lack of perfusion to portions of the myocardium, despite reopen ing of the occluded infarctrelated epicardial coro nary artery [266] [267] [268] . Therapies targeting noreflow have the potential to further preserve cardiac structure and function following MI. In a canine model of prox imal coronary artery occlusion of 90 min, the fluorescent dye thioflavin S, which stains endothelial cells receiving flow, failed to penetrate much of the subendocardium when injected into the vasculature after the proximal coronary artery was reopened 269 . Perfusion defects were observed as early as 10-12 s after the reopening of the proximal coronary artery and seemed to increase in size as the duration of the reperfusion phase was extended to several hours 270 , suggesting that noreflow is a true form of reperfusion injury. Other techniques confirm the phenomenon of noreflow, including failure of car bon black and radioactive microspheres to penetrate portions of previously ischaemic myocardium 269, 271 . What causes noreflow and what is its importance in the pathophysiology of disease? Our group has studied the ultrastructural features of the myo cardium within the anatomical noreflow zone, and found local ized swelling or blistering of the endothelium of small blood vessels and capillaries 269 . Membranebound intraluminal blebs, protruding from the endothelial cells, obstructed the lumen of small blood vessels. Mitochondrial abnormalities might contribute to no reflow. Zhao and colleagues showed that inhibiting the opening of the mitochondrial ATPsensitive potassium channels prevents simvastatin from exerting a beneficial effect on reducing noreflow 272 . Given that the zone of noreflow is confined within areas of dead cardio myocytes, and ultrastructural evidence of the micro vasculature injury lags behind ultrastructural evidence of cardiomyocyte cell death, noreflow is unlikely to contribute directly to additional myocyte cell death. However, given that bloodborne trophic factors and cells crucial to the removal of necrotic debris and scar can neither enter nor exit the zone of noreflow, no reflow inhibits the healing phase of MI. In our study, we observed that rats subjected to proximal coronary occlusion and reperfusion demonstrated persistent areas of noreflow at 1 month after acute infarction. Hearts with larger zones of noreflow and fewer per fused capillaries had greater myocardial infarct expan sion (stretching and thinning of the infarcted wall) and dilatation of the left ventricle, signs of poor healing, and adverse LV remodelling 273 . The noreflow phenomenon has been well docu mented in patients undergoing reperfusion therapy (either thrombolytic or PCI) for acute STEMI 268, [274] [275] [276] . Several different noninvasive imaging techniques, such as echocardiography contrast imaging, nuclear imaging with 201 Tllabelled or 99m Tclabelled albu min microspheres, and MRI with contrast, have been used to document perfusion defects after reperfu sion therapy. Preclinical studies verified that MRI visualized perfusion deficits correlate closely (by loca tion and shape) with perfusion defects observed using thioflavin S staining 277, 278 . Noreflow has also been associated with adverse LV remodelling in the clinical setting, which is an impor tant observation because the degree of LV remodelling, including dilatation of the LV cavity, is predictive of increased mortality and congestive heart failure after MI [279] [280] [281] . In one study, LV volumes were larger (170 ml) in patients with noreflow than in patients without noreflow (115 ml) at 6 months after MI. Noreflow was the most important predictor of LV dilatation, even more so than infarct size, and was the only predictor of cardiac death 279 . Several clinical studies have also shown that noreflow in the setting of MI is associated with a poor prognosis 275, [278] [279] [280] 282, 283 . Wu and colleagues demon strated that patients with noreflow had more major adverse cardiac events (cardiac death, nonfatal myo cardial reinfarction, congestive heart failure, stroke, and unstable angina) over 2 years compared with patients without noreflow 278 . This finding was consistent in a multiple regression analysis that accounted for the size of the MI. Ndrepepa and colleagues reported that the presence of noreflow was predictive of 5year mortality (OR 1.72-2.01, P = 0.004), again independent of infarct size. They concluded that the presence of noreflow following intervention for STEMI provides prognostic information independent of and beyond that provided by infarct size 282 . Several therapies have been targeted at reducing the size of the noreflow zone. Experimentally, thera pies that reduce MI above and beyond reperfusion often reduce the zone of noreflow within the infarct. In our experience, such therapies must be given before reperfusion to be of use. However, a major issue limiting application of adjunctive therapies is that stopping to administer a drug or therapy before reperfusion is often seen as a delay in doortoballoon time, and interven tional cardiologists are not willing to risk extending that time. We previously described a therapy that reduces noreflow independent of any effect on the size of the infarct, which can be administered after the infarct artery is patent 284 . Delayed therapeutic hypo thermia administered locally to the risk zone significantly reduced the zone of noreflow in both rabbit and rat models of MI. In the rabbit model, local hypothermia applied as late as 30 min after establishing patency of the infarctrelated artery markedly reduced the size of the noreflow zone within the infarct 284 . Myocardial temperature is lowered to 30-34°C for several hours. We believe that this reduction in temperature is likely to reduce endothelial swelling and inflammation, much like how ice reduces blistering after a burn. We plan to determine the longterm consequences of delayed therapeutic hypothermia and predict that it will reduce adverse LV remodelling and longterm cardiac function by enhancing tissue healing. Targeting the noreflow phenomenon in a way that will not extend doorto balloon times and is not dependent on a reduction of infarct size provides a novel therapeutic approach that could help to fill the unmet need of unacceptably high morbidity and mortality following MI, despite successful PCI. However, the mechanisms underlying the protective effects of hypothermia on noreflow are unknown. Based on our observations of the natural his tory of noreflow, as well as studies that we and others have conducted in an attempt to understand how early hypothermia can reduce myocardial infarct size, sev eral potential targets of hypothermia have been postu lated, including mitogenactivated protein kinases 285 , local tissue and endothelial oedema, ROS damage and cellular inflammation, and mitochondrial structure and function.
Conclusions
Despite the success of early reperfusion to reduce myocardial infarct size and improve clinical outcome, the high rates of heart failure and mortality following STEMI remain unacceptable. Given that most clinical trials of adjunctive therapies (adjunctive to thera peutic reperfusion) aimed at further reducing myocardial infarct size have been disappointing, new approaches are needed. In this Review, we presented several new therapeutic targets involved in ischaemia-reperfusion injury that have shown promise in preclinical stud ies, including therapies to reduce myocardial infarct size based on mitochondrial protective properties; approaches that involve the mechanisms of autophagy, mitophagy, and pyroptosis; strategies that take advan tage of the cardioprotective properties of certain anaes thetic agents; treatments that show cardioprotective benefits in addition to the effects of certain antiplatelet agents; and therapies that are focused on correcting the noreflow phenomenon and its effect on healing and adverse LV remodelling. 
